Endometrial Cancer — Clinical Detail Page

If you are a patient (or family member of a patient) and you want plain-language answers — not clinical terminology — read the main Uterus Cancer page instead. It covers:

• Is bleeding after menopause cancer? (the #1 entry symptom)
• What does my biopsy or D&C report mean? (plain-English explainer)
• Can uterus cancer be cured?
• Will I lose my uterus? Will I need a hysterectomy?
• Do I need to remove my ovaries too?
• Can I have children after treatment?
• Cost in Ahmedabad, recovery timeline, side effects

👉 Read the patient-language Uterus Cancer page →

If you want the clinical depth — molecular subtypes, TCGA classification, biomarker testing, treatment by molecular profile — continue reading below.

Endometrial cancer is a malignancy of the inner lining of the uterus (the endometrium). It is the most common gynaecological cancer in urban India and the fourth most common cancer in women globally. Incidence is rising with the prevalence of obesity, type 2 diabetes, and sedentary lifestyles — all of which raise circulating oestrogen, the main driver of the most common (Type I, endometrioid) endometrial cancer subtype.

Prognosis is generally favourable: approximately 70% of cases are diagnosed at Stage I (cancer confined to the uterus), and five-year survival at this stage exceeds 90-95%. The single most important factor in this favourable outcome is prompt investigation of postmenopausal bleeding — the cardinal symptom.

Dr. Nishtha Tripathi Patel performs comprehensive endometrial cancer surgery — total laparoscopic hysterectomy, bilateral salpingo-oophorectomy, sentinel lymph node mapping, and robotic radical hysterectomy where indicated — at Sterling Hospitals and KD Hospital, Ahmedabad.

Modern endometrial cancer management incorporates molecular subtyping, which has fundamentally changed how risk is assessed and treatment is personalised. The four TCGA / ProMisE molecular groups:

1. POLE ultramutated

Mutations in the POLE gene producing a hypermutated tumour. Excellent prognosis even at higher histological grade. Often does not require adjuvant treatment after surgery.

2. Mismatch repair deficient (MMR-d / MSI-high)

Loss of mismatch repair function. Intermediate prognosis. Strongly associated with Lynch syndrome — genetic testing of the patient and family is recommended. Increasingly responsive to immunotherapy in recurrent or advanced disease.

3. p53 abnormal (copy-number-high, serous-like)

TP53 mutations. The most aggressive molecular group. Includes serous and many clear cell carcinomas. Usually requires adjuvant chemotherapy (and sometimes radiation) even in early stages.

4. No specific molecular profile (NSMP / copy-number-low)

Endometrioid carcinomas without POLE mutation, MMR deficiency, or p53 abnormality. Intermediate prognosis. Treatment guided by stage and histological grade.

Why this matters: molecular profiling now drives risk-stratified treatment decisions in line with current ESGO / ESMO / NCCN guidelines. Two patients with identical stage and grade can have very different prognoses and treatment plans based on their molecular subtype.

📱 Contact Our Care Team

The main risk factor for the most common (Type I, endometrioid) endometrial cancer is unopposed oestrogen exposure. Contributing factors:

• Obesity — the most significant modifiable risk factor. Adipose tissue converts androgens to oestrogen, driving endometrial proliferation.
• Type 2 diabetes and metabolic syndrome — independently raise risk through insulin resistance and chronic inflammation.
• Polycystic ovary syndrome (PCOS) — chronic anovulation produces unopposed oestrogen.
• Oestrogen-only HRT (without progestin in women with an intact uterus).
• Nulliparity — never having been pregnant.
• Early menarche / late menopause — longer cumulative oestrogen exposure.
• Tamoxifen — used for breast cancer treatment; modest increase in endometrial cancer risk.
• Family history — particularly Lynch syndrome (see dedicated section below).

Type II (serous, clear cell, carcinosarcoma) endometrial cancers are not primarily oestrogen-driven and often arise in thin postmenopausal women without the classic risk factors above. These are biologically distinct from Type I and require different treatment approaches.

Diagnostic work-up for suspected endometrial cancer follows a stepwise pathway:

1. Pelvic ultrasound (transvaginal) — measures endometrial thickness. In a postmenopausal woman with bleeding, an endometrial stripe >4 mm warrants tissue sampling.
2. Endometrial biopsy — office-based Pipelle sampling. First-line diagnostic test.
3. Hysteroscopy with directed biopsy / fractional curettage (D&C) — when office biopsy is non-diagnostic or insufficient sampling is suspected.
4. Pelvic MRI — once cancer is confirmed. Assesses depth of myometrial invasion, cervical involvement, and parametrial extension. Critical for surgical planning.
5. CT chest / abdomen / pelvis — staging investigation, particularly in high-grade or symptomatic disease.
6. PET-CT — used selectively in high-risk histologies and suspected nodal or distant disease.
7. Biomarker / molecular testing — immunohistochemistry for MMR proteins, p53, and ER/PR. POLE mutation testing where available. Increasingly standard for risk stratification.
8. Genetic counselling and germline testing — indicated in MMR-deficient tumours, age < 50 at diagnosis, or family history suggestive of Lynch syndrome.

Tumour grade (G1, G2, G3) and histological subtype (endometrioid, serous, clear cell, carcinosarcoma) are determined from the diagnostic specimen and refined on the hysterectomy specimen.

Endometrial cancer staging follows the FIGO 2023 system, which integrates traditional anatomic spread with molecular subtype.

Stage I — Cancer is confined to the uterine corpus. Substaged by depth of myometrial invasion (IA: <50% invasion; IB: ≥50% invasion). Molecular subtype is now included as a stage modifier in the 2023 system.

Stage II — Cancer invades the cervical stroma.

Stage III — Local or regional spread:

• IIIA: serosa or adnexa
• IIIB: vagina or parametrial involvement
• IIIC: pelvic (IIIC1) or para-aortic (IIIC2) lymph nodes

Stage IV — Distant spread:

• IVA: bladder or bowel mucosa
• IVB: distant metastases including peritoneal disease beyond the pelvis, lungs, liver, or distant lymph nodes

Final staging is surgical-pathologic — confirmed after hysterectomy with lymph node assessment. The 2023 system also incorporates molecular subtype, lymphovascular space invasion, and aggressive histology as stage modifiers.

Endometrial cancer treatment is individualised based on stage, histological grade, and molecular profile.

Surgery (the cornerstone for most cases)

Standard surgery is total hysterectomy with bilateral salpingo-oophorectomy. Surgical staging includes peritoneal washings and pelvic / para-aortic lymph node assessment — increasingly via sentinel lymph node mapping (ICG-guided) which is now the preferred approach in early-stage disease.

Surgical approach options:

• Robotic surgery — preferred for most stage I-II cases at Sterling Hospitals. See full Robotic Surgery page →
• Total laparoscopic hysterectomy (TLH) — alternative minimally invasive approach
• Open (laparotomy) — reserved for very large uteri, advanced disease, or contraindications to minimally invasive surgery

Adjuvant therapy

• Vaginal brachytherapy — selected stage I-II low-intermediate risk cases to reduce vaginal cuff recurrence
• External beam radiotherapy — high-intermediate risk and stage II-III cases
• Chemotherapy (carboplatin + paclitaxel) — stage III-IV, aggressive histologies (serous, clear cell, carcinosarcoma), p53-abnormal molecular group
• Immunotherapy (pembrolizumab, dostarlimab) — MMR-deficient advanced or recurrent disease
• Hormonal therapy (megestrol, medroxyprogesterone, GnRH analogues, aromatase inhibitors) — fertility-preserving management in selected early-stage low-grade disease, or palliative management in low-grade hormone-receptor-positive advanced disease
• Targeted therapy — emerging role for lenvatinib + pembrolizumab combinations and HER2-targeted therapy in selected cases

For most stage I-II endometrial cancer cases, robotic surgery is the preferred surgical approach. Benefits over open surgery include smaller incisions, less blood loss, shorter hospital stay (2-4 days vs 5-7 days), and faster return to normal activity (3-4 weeks vs 6-8 weeks). Cancer-clearance outcomes are equivalent to open surgery in suitable cases.

Robotic surgery is not the right choice when:

• The uterus is very large (uterine fibroids or bulky tumour)
• The cancer has spread widely beyond the uterus (stage IV)
• The patient has significant adhesions from prior abdominal surgery
• The patient has medical comorbidities that preclude prolonged anaesthesia

👉 Read the full Robotic Surgery page → for detailed comparison with open and keyhole surgery, cost, insurance, and recovery information.

Approximately 3-5% of endometrial cancers are associated with Lynch syndrome — an inherited mismatch repair gene defect (MLH1, MSH2, MSH6, PMS2, or EPCAM) that also raises lifetime risk of colorectal, ovarian, urinary tract, and other cancers.

Universal MMR / MSI testing of all endometrial cancer specimens is now standard of care — both to flag Lynch syndrome and to identify candidates for immunotherapy in advanced or recurrent disease.

Indications for confirmatory germline testing:

• MMR-deficient tumour without MLH1 promoter hypermethylation
• Diagnosis before age 50
• Personal or family history of Lynch-spectrum cancers (endometrial, colorectal, ovarian, urothelial, gastric, biliary, brain, small bowel)
• Multiple synchronous or metachronous Lynch-spectrum cancers in the same patient

If a germline mutation is identified, cascade testing should be offered to first-degree relatives. Lynch syndrome carriers benefit from enhanced surveillance (annual colonoscopy from age 25, endometrial sampling, risk-reducing surgery after childbearing).

Recovery timelines depend on the surgical approach.

After robotic or keyhole (laparoscopic) hysterectomy

• Hospital stay: 2-4 days
• Walking with support: day 1
• Back to gentle daily activity: 2-3 weeks
• Driving: 3-4 weeks
• Back to light work: 3-4 weeks
• Full recovery: 6-8 weeks

After open hysterectomy

• Hospital stay: 5-7 days
• Back to gentle daily activity: 4-6 weeks
• Driving: 6 weeks
• Back to light work: 6-8 weeks
• Full recovery: 3 months

If adjuvant radiation or chemotherapy is needed

Allow 4-6 weeks recovery from surgery before starting. Radiation is given 5 days a week for about 5 weeks. Chemotherapy is given every 3 weeks for 4-6 cycles.

For a more detailed patient-language recovery walk-through, see the Uterus Cancer page.

Cost depends on the surgical approach and whether adjuvant treatment is needed. The numbers below are taken from the cost package already published on this site for endometrial cancer surgery.

For an exact quote, send your biopsy report, molecular pathology (if done), and MRI on WhatsApp.

📱 Contact Our Care Team

See the full cost detail page: Endometrial cancer surgery cost in Ahmedabad →

Most private health insurance in India covers endometrial cancer treatment for medically justified cases — but the exact coverage depends on your policy and the insurer’s approval.

What is usually covered

• ✓ Surgery (open, keyhole, or robotic) — when medically justified
• ✓ Pre-operative tests (MRI, PET-CT, blood work)
• ✓ Hospital stay, ICU if needed
• ✓ Adjuvant radiation and chemotherapy after surgery
• ✓ Sentinel lymph node mapping (usually)

Points that may need confirmation

• Robotic surgery premium — some older policies cap reimbursement at the laparoscopic rate. Confirm with your insurer before admission.
• Molecular / biomarker testing — coverage varies. Some insurers cover only if specifically pre-authorised.
• Immunotherapy (pembrolizumab, dostarlimab) for advanced / recurrent MMR-deficient disease — usually requires specific pre-authorisation; coverage varies by policy.
• PMJAY (Ayushman Bharat) and MA-Amrutam — cover endometrial cancer treatment at approved hospitals up to defined caps.

Sterling Hospitals’ cashless team helps with insurance paperwork and pre-authorisation. Most approvals take 2-5 days.

Many patients travel to Ahmedabad from across Gujarat, Maharashtra, Rajasthan, and Madhya Pradesh for women’s cancer care.

If you already have scans, biopsy reports, discharge summaries, or treatment records, our care team may request copies of these while helping coordinate your appointment. This helps the care team prepare for your consultation and guide you on the next administrative steps.

Records that are useful to bring (or share when the team requests them):

• Biopsy or D&C report
• Molecular pathology report (if done)
• Pelvic MRI / CT report — and the actual scan images if available
• A list of current medicines and allergies
• Any previous treatment summary

How the visit usually works:

1. Contact our care team to discuss what you need
2. Share your available records if the team requests them while coordinating your appointment
3. Attend your in-clinic specialist consultation
4. You leave with a written treatment plan from the specialist

📱 Contact Our Care Team

A second-opinion review before endometrial cancer surgery is sensible in any of these situations:

• Your biopsy or D&C report shows atypical hyperplasia, EIN, or any cancer cell type, and surgery has been recommended
• Your report mentions an aggressive subtype — serous, clear cell, carcinosarcoma, or grade 3 endometrioid
• You are premenopausal and want to preserve fertility (limited cases qualify for hormone therapy)
• The cancer is at an advanced stage (III or IV) and you want to confirm the treatment plan
• You have a strong family history of Lynch-spectrum cancers (uterus, colon, ovary) and want clarity on genetic testing
• You have been told the surgery will be open but want to know whether keyhole or robotic is safe in your case
• You are unsure whether the extent of lymph node sampling proposed is appropriate

Send the biopsy, MRI, molecular pathology (if done), and proposed surgical plan on WhatsApp. the specialist reviews at your consultation and reply with an in-clinic second-opinion consultation.

📱 Contact Our Care Team

• ESGO certified (European Society of Gynaecological Oncology) — training tested against international standards
• 12+ years of experience in women’s cancer surgery
• Performs all surgical approaches — open, keyhole, and robotic — and recommends the right one for your case
• Uses sentinel lymph node mapping where indicated — preserves nodal information while reducing lymphoedema risk
• Coordinates molecular profiling and adjuvant therapy with the medical oncology and radiation oncology teams at Sterling Hospitals
• Honest case selection — if a less aggressive approach is right for you, the specialist will recommend it
• Female women’s cancer specialist — important to many patients and families
• WhatsApp accessible — direct review of biopsy, MRI, and molecular pathology reports before your specialist consultation
• Out-of-city families welcomed — pre-travel WhatsApp review saves wasted trips

Read Dr. Nishtha’s Full Profile →   Book Appointment

Whether you have a new diagnosis, a recent report, or would like an in-clinic second opinion on a treatment plan — book an appointment with the clinic. The specialist will go through everything with you at your visit.

Dr. Nishtha sees patients at Sterling Hospitals (main centre), KD Hospital, and Welcare Hospital.

📅 Book Appointment   📱 Contact Our Care Team

You can also call the clinic on +91 76988 00333.